Lantus insulin glargine: Additional Phase III data

Additional data from the open-label, international Phase III ORIGIN trial in 12,537 pre-diabetics or early Type II diabetics with cardiovascular risk factors showed that patients on Lantus were about 3 times more likely to achieve and maintain HbA1c <6.5% over 5 years compared to standard of care (SOC) consisting of investigator's best judgment over the 6-year study (p<0.001). Lantus was more effective at maintaining glycemic control than SOC in all subgroups, including age, alcohol consumption, depression, baseline HbA1c, urine albumin to creatinine ratio and diabetes. Lantus was significantly more effective than SOC at maintaining glycemic control in subgroups of patients with abdominal obesity (p=0.011) and greater grip strength (p<0.001). Data were presented at the European Association for the Study of Diabetes meeting in Berlin. ...